TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38469686

Group type: EXPERIMENTAL
Intervention: Immediate curative therapy (radiotherapy or prostatectomy)
Number of subjects: 980

Group type: COMPARATOR
Intervention: Conservative therapy (endocrine therapy or observation)
Number of subjects: 980
Study: 38469689

Group type: EXPERIMENTAL
Intervention: AI-enabled quantitative plaque analysis
Number of subjects: 4430

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 4430
Study: 38469809

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38470299

Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 138
Study: 38470404

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenvatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel or doxorubicin)
Number of subjects: 0
Study: 38470420

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg subcutaneously for 6 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional treatment of cardiovascular risk factors (control group) for 6 months
Number of subjects: 55
Study: 38470426

Group type: EXPERIMENTAL
Intervention: Engagement in light physical activity
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Performance in the 4-m gait test
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Score on the short version of the Mini-Nutritional Assessment
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Reported fatigue
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Mini-Nutritional Assessment score
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Participation in moderate physical activity
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Slow gait speed
Number of subjects: 235
Study: 38470444

Group type: EXPERIMENTAL
Intervention: Posoleucel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38470447

Group type: EXPERIMENTAL
Intervention: Dalpiciclib plus non-steroidal aromatase inhibitor (NSAI)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Abemaciclib plus non-steroidal aromatase inhibitor (NSAI)
Number of subjects: 2
Study: 38470460

Group type: EXPERIMENTAL
Intervention: Nthabi health promotion app used on smartphones or tablets for up to 6 weeks
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Nthabi health promotion app
Number of subjects: 172
Study: 38470468

Group type: EXPERIMENTAL
Intervention: Social media intervention (4, 8, 16, and 32 exposures over 15 days)
Number of subjects: 1491

Group type: COMPARATOR
Intervention: Control group (0 exposures)
Number of subjects: 1491
Study: 38470476

Group type: EXPERIMENTAL
Intervention: CAC tool Easy-ICD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual coding processes
Number of subjects: 0
Study: 38470512

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 0
Study: 38470867

Group type: EXPERIMENTAL
Intervention: Caregiver contribution to self-care
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Patient self-care
Number of subjects: 510
Study: 38470985

Group type: EXPERIMENTAL
Intervention: LetibotulinumtoxinA
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study: 38471042

Group type: EXPERIMENTAL
Intervention: Surgical methods for limb salvage
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Low-age group (≤10 years)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: High-age group (>10 years)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Modular prosthesis
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Incidence of local relapse rate (LRR)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Incidence of metastasis
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Prosthesis-related complications
Number of subjects: 345
Study: 38471063

Group type: EXPERIMENTAL
Intervention: Third-party, single-donor fecal microbiota transplantation (FMT) administered in combination with systemic corticosteroids. Induction dose: 15 capsules per day for 2 consecutive days, followed by 3 weekly maintenance doses of 15 capsules each.
Number of subjects: 10
Study: 38471061

Group type: EXPERIMENTAL
Intervention: Gilteritinib
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 38471091

Group type: EXPERIMENTAL
Intervention: Care coordination programs (CCPs) for HIV care
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Routine provision of emotional support by providers
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Screening and referrals to psychiatric and/or psychological care
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Training for providers
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Documentation of emotional support provision
Number of subjects: 57
Study: 38471293

Group type: EXPERIMENTAL
Intervention: Short sleep duration (≤6 h per night)
Number of subjects: 2504

Group type: COMPARATOR
Intervention: Normal sleep duration (>6 and ≤8 h)
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Long sleep duration (>8 h)
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Short sleep duration (≤6 h per night) in old age
Number of subjects: 2504

Group type: EXPERIMENTAL
Intervention: Long sleep duration (>8 h) in old age
Number of subjects: 2504
Study: 38471311

Group type: EXPERIMENTAL
Intervention: mHealth-based relaxation program (8 weeks, including progressive muscle relaxation, guided imagery, and mindfulness)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 50
Study: 38471416

Group type: EXPERIMENTAL
Intervention: Durvalumab Q4W + cisplatin + etoposide + radiotherapy (Arm 1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Durvalumab Q4W + carboplatin + paclitaxel + radiotherapy (Arm 2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Durvalumab Q4W + carboplatin or cisplatin + pemetrexed + radiotherapy (Arm 3)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with cCRT
Number of subjects: 64
Study: 38471508

Group type: EXPERIMENTAL
Intervention: i.p. nivolumab monotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: i.p. nivolumab every 2 weeks and i.p. ipilimumab every 6 weeks
Number of subjects: 23
Study: 38471641

Group type: EXPERIMENTAL
Intervention: Be Well Home Health Navigator Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38471681

Group type: EXPERIMENTAL
Intervention: Ultra-processed diet (UPF)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Minimally processed diet (following UK dietary guidance)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 6-month behavioural support programme aimed at reducing UPF intake
Number of subjects: 55
Study: 38471711

Group type: EXPERIMENTAL
Intervention: Cemiplimab 600 mg intravenously Q4W for up to 48 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cemiplimab 600 mg intravenously Q4W
Number of subjects: 63
Study: 38471727

Group type: EXPERIMENTAL
Intervention: ESC 0/1-h algorithm with hs-cTnT
Number of subjects: 1430

Group type: EXPERIMENTAL
Intervention: ESC 0/1-h algorithm with HEART score
Number of subjects: 1430

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1430
Study: 38471825

Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 74

Group type: COMPARATOR
Intervention: Suspension of Rilonacept
Number of subjects: 74
Study: 38471990

Group type: EXPERIMENTAL
Intervention: Mito-MES 20 mg daily for 14 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: No Mito-MES (control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mito-MES
Number of subjects: 80
Study: 38472049

Group type: EXPERIMENTAL
Intervention: 12-week abdominal and pelvic floor muscle exercise program during pregnancy
Number of subjects: 96

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study: 38472241

Group type: EXPERIMENTAL
Intervention: Alteplase treatment
Number of subjects: 592
Study: 38472381

Group type: EXPERIMENTAL
Intervention: Discontinuation of absorbent pyjama pants (APP) after a 4-week run-in period.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuation of absorbent pyjama pants (APP) after a 4-week run-in period.
Number of subjects: 0
Study: 38472528

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study: 38472611

Group type: EXPERIMENTAL
Intervention: Deuterium metabolic imaging (DMI) of glucose and its downstream metabolites
Number of subjects: 6
Study: 38472696

Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg (single and multiple doses)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg (single dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Midazolam 2 mg and Warfarin 25 mg (concomitant administration)
Number of subjects: 18
Study: 38473239

Group type: EXPERIMENTAL
Intervention: CC-96191, a novel CD33/CD16a/NKG2D immune-modulating TriNKET
Number of subjects: 0
Study: 38473248

Group type: EXPERIMENTAL
Intervention: Besifovir (BSV) treatment for up to 8 years
Number of subjects: 188
Study: 38473278

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with impaired renal function (not specified)
Number of subjects: 0
Study: 38473704

Group type: EXPERIMENTAL
Intervention: CRISPR/Cas9-based genome editing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lentivirus (LV) and Adeno-associated virus (AAV) based gene therapy
Number of subjects: 0
Study: 38475751

Group type: EXPERIMENTAL
Intervention: Total-breath (TB) method
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 118
Study: 38475757

Group type: EXPERIMENTAL
Intervention: No menthol restriction (menthol cigarette and menthol flavored e-cigarette)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Menthol prohibited in cigarettes only (non-menthol cigarette and menthol flavored e-cigarette)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Menthol prohibited in both cigarettes and e-cigarettes (non-menthol cigarette and tobacco flavored e-cigarette)
Number of subjects: 150
Study: 38475758

Group type: EXPERIMENTAL
Intervention: Digital pre-consult patient decision aid
Number of subjects: 204

Group type: COMPARATOR
Intervention: Paper-based in-consult patient decision aid
Number of subjects: 204
Study: 38475764

Group type: EXPERIMENTAL
Intervention: Intra-articular gold micro-particles with hyaluronic acid (20 mg, 72,000 particles, 20-40 μm in diameter)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Intra-articular gold micro-particles with hyaluronic acid
Number of subjects: 136
Study: 38475765

Group type: EXPERIMENTAL
Intervention: Pre-operative Stereotactic Radiosurgery (SRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-operative Stereotactic Radiosurgery (SRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall Survival
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morbidity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Completion of planned therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time to systemic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time to regional progression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time to CNS progression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time to subsequent treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate of radiation necrosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate of local recurrence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate of leptomeningeal disease
Number of subjects: 0
Study: 38475768

Group type: EXPERIMENTAL
Intervention: Three sessions of behavioral parent training with optional booster sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 38475786

Group type: EXPERIMENTAL
Intervention: Anakinra (human interleukin 1 receptor antagonist)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 393
Study: 38475815

Group type: EXPERIMENTAL
Intervention: FLASH radiotherapy (8 Gy in a single fraction at ≥ 40 Gy/s)
Number of subjects: 10
Study: 38475822

Group type: EXPERIMENTAL
Intervention: Angiotensin II (AT2) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) vasopressor therapy
Number of subjects: 0
Study: 38475923

Group type: EXPERIMENTAL
Intervention: Active stimulation of the neuroimmune modulation device (SetPoint Medical) for 1 min once per day.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-active (sham) stimulation for 1 min once per day.
Number of subjects: 60
Study: 38476120

Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy (RT)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Non-radiotherapy (non-RT)
Number of subjects: 270
Study: 38476213

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 38476396

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 360
Study: 38476466

Group type: EXPERIMENTAL
Intervention: Pimavanserin (34 mg, once daily)
Number of subjects: 29
Study: 38476496

Group type: EXPERIMENTAL
Intervention: COVID-19 self-test kits distributed within social networks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Receiving test kits from social contacts
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ordering self-test kits from the government
Number of subjects: 61

Group type: COMPARATOR
Intervention: Secondary distribution of COVID-19 self-test kits
Number of subjects: 61
Study: 38476746

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS, 1 mA, 20 min)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo stimulation (control)
Number of subjects: 123
Study: 38476961

Group type: EXPERIMENTAL
Intervention: Dichoptic therapy with eye-tracking, 1.5 hours, 6 days per week for 1 month
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Dichoptic therapy with eye-tracking, continued for 4 months
Number of subjects: 1
Study: 38477110

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 34
Study: 38477162

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639
Study: 38477412

Group type: EXPERIMENTAL
Intervention: Buss-Perry Aggression Questionnaire-short form (BPAQ-SF)
Number of subjects: 0
Study: 38477494

Group type: EXPERIMENTAL
Intervention: Transvaginal permanent mesh
Number of subjects: 7846

Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 7846
Study: 38477675

Group type: EXPERIMENTAL
Intervention: Low-Dose Morphine
Number of subjects: 0
Study: 38477704

Group type: EXPERIMENTAL
Intervention: Invasive central systolic blood pressure (invCSBP) measurement
Number of subjects: 168

Group type: COMPARATOR
Intervention: Cuff-based brachial systolic blood pressure (cuffSBP) measurement
Number of subjects: 168
Study: 38477706

Group type: EXPERIMENTAL
Intervention: Dried blood spots (DBS) sampling for metronidazole concentrations
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Optimized population pharmacokinetic model of metronidazole
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 6-hour dosing interval for metronidazole
Number of subjects: 143
Study: 38477913

Group type: EXPERIMENTAL
Intervention: QCA-guided PCI
Number of subjects: 1528

Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 1528
Study: 38477966

Group type: EXPERIMENTAL
Intervention: CARv3-TEAM-E T cells
Number of subjects: 3
Study: 38477975

Group type: EXPERIMENTAL
Intervention: Remote RC2S (Cognitive remediation of social cognition in Schizophrenia) for 24 biweekly individual 1-hour sessions with a therapist.
Number of subjects: 20
Study: 38477985

Group type: EXPERIMENTAL
Intervention: cfDNA blood-based test
Number of subjects: 7861
Study: 38477987

Group type: EXPERIMENTAL
Intervention: Iptacopan monotherapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Anti-C5 therapy
Number of subjects: 93
Study: 38477988

Group type: EXPERIMENTAL
Intervention: RSVPreF3-Mat vaccine
Number of subjects: 5328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5328
Study: 38477986

Group type: EXPERIMENTAL
Intervention: Next-generation multitarget stool DNA test
Number of subjects: 20176

Group type: COMPARATOR
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 20176
Study: 38478023

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 189
Study: 38478042

Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) dosages ranging from 0-1.6 mg combined with 10 mg enalapril maleate, taken daily for 8 weeks
Number of subjects: 2697
Study: 38478255

Group type: EXPERIMENTAL
Intervention: Outpatient parenteral antimicrobial therapy (OPAT) with anti-infective medications administered at home using elastomeric pumps for a median duration of 15 days.
Number of subjects: 77
Study: 38478366

Group type: EXPERIMENTAL
Intervention: Silymarin (150 to 300 mg twice a day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 38478488

Group type: EXPERIMENTAL
Intervention: Maintain serum potassium ≥ 3.6 mEq/L
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Maintain serum potassium ≥ 4.5 mEq/L
Number of subjects: 1684
Study: 38478535

Group type: EXPERIMENTAL
Intervention: Genetic analysis through low-pass whole genome sequencing and whole exome sequencing.
Number of subjects: 3734

Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) built through a hybrid approach including effect size of each SNP, number of effect alleles observed, sample ploidy, total number of SNPs included in the PRS, and number of non-missing SNPs in the sample.
Number of subjects: 3734

Group type: EXPERIMENTAL
Intervention: Screening for pathogenic or likely pathogenic variants in 8 genes (ABCG5, ABCG8, APOB, APOE, LDLR, LDLRAP1, LIPA, PCSK9).
Number of subjects: 3734

Group type: EXPERIMENTAL
Intervention: Multiple logistic regression analysis.
Number of subjects: 3734
Study: 38478634

Group type: EXPERIMENTAL
Intervention: PVRV-NG2 + HRIG
Number of subjects: 640

Group type: COMPARATOR
Intervention: PVRV + HRIG
Number of subjects: 640

Group type: COMPARATOR
Intervention: HDCV + HRIG
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: PVRV-NG2 alone
Number of subjects: 640
Study: 38478705

Group type: EXPERIMENTAL
Intervention: mRNA-1647 (30, 90, 180, or 300 µg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 38479114

Group type: EXPERIMENTAL
Intervention: Combined 6-day program of exercise, self-management workshops, and spa therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Self-management alone (control group)
Number of subjects: 150
Study: 38479118

Group type: EXPERIMENTAL
Intervention: Tunlametinib
Number of subjects: 100
Study: 38479192

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine infusions (3 during acute phase, 4 additional if remitted)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine infusions
Number of subjects: 74
Study: 38479195

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 148
Study: 38479344

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation exercise program with teleconsultations with a specialist nurse for 4 weeks.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group participated in physical activity howsoever they wished.
Number of subjects: 79
Study: 38479748

Group type: EXPERIMENTAL
Intervention: SMC with directly observed treatment (DOT) for the full course in under 5-year-old children
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: SMC with directly observed treatment (DOT) for the full course in under 10-year-old children
Number of subjects: 62

Group type: COMPARATOR
Intervention: SMC without directly observed treatment (DOT) for the full course in under 5-year-old children
Number of subjects: 62
Study: 38479746

Group type: EXPERIMENTAL
Intervention: Dual Prevention Pill (DPP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oral Pre-Exposure Prophylaxis (PrEP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oral Contraception (OC)
Number of subjects: 126
Study: 38479751

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38479794

Group type: EXPERIMENTAL
Intervention: Vibratory stimulus at the site of skin puncture beginning 10 seconds prior to a heel stick
Number of subjects: 134

Group type: COMPARATOR
Intervention: No vibration (control)
Number of subjects: 134
Study: 38479803

Group type: EXPERIMENTAL
Intervention: Primary cytoreductive surgery
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy followed by interval cytoreductive surgery
Number of subjects: 5000
Study: 38479820

Group type: EXPERIMENTAL
Intervention: Normal hsCRP values
Number of subjects: 1047
Study: 38479939

Group type: EXPERIMENTAL
Intervention: Fish hydrolysate supplementation for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38479953

Group type: EXPERIMENTAL
Intervention: Contrast volume reduction (CVR) group using the DyeVert CM diversion system (n=276)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group using a conventional manual or automatic injection syringe (n=274)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Contrast volume reduction (CVR) group
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 550
Study: 38480098

Group type: EXPERIMENTAL
Intervention: Dual vein embolization (DVE)
Number of subjects: 10
Study: 38480590

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-based personalized antiplatelet therapy; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antiplatelet therapy without genotype information; specific details not mentioned.
Number of subjects: 0
Study: 38480624

Group type: EXPERIMENTAL
Intervention: Chiropractic care (specific intervention details not provided)
Number of subjects: 573